The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Statin-induced apoptosis and skeletal myopathy
Abstract
Over 100 million prescriptions were filled for statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) in 2004. Statins were originally developed to lower plasma cholesterol in patients with hypercholesterolemia and are the most effective drugs on the market in doing so. Because of the discovered pleiotropic effects of statins, the use has expanded to the treatment of many other conditions, including ventricular arrythmias, idiopathic dilated cardiomyopathy, cancer, osteoporosis, and diabetes. The elderly population is growing. Therefore, it is estimated that the number of statin users will also increase. Fortunately, the use of statins is relatively safe with few side effects. Myopathy is the most common side effect with symptoms ranging from fatigue, weakness, and pain to symptoms associated with rhabdomyolysis which is a life-threatening condition. The development of statin-induced rhabdomyolysis is rare occurring in ∼0.1% of patients; however, the occurrence of less severe symptoms is underreported and may be 1–5% or more. Physical exercise appears to increase the likelihood for the development of myopathy in patients taking statins. It is thought that as many as 25% of statin users who exercise may experience muscle fatigue, weakness, aches, and cramping due to statin therapy and potentially dismissed by the patient and physician. The mechanisms causing statin-induced myopathy have not been elucidated; however, research efforts suggest that apoptosis of myofibers may contribute. The mitochondrion is considered a regulatory center of apoptosis, and therefore its role in the induction of apoptosis will be discussed as well as the mechanism of statin-induced apoptosis and myopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dirks, A. J., & Leeuwenburgh, C. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.10.003 · Cited by 190 · cited 1×
“Endoplasmic reticulum stress and calcium dyshomeostasis could also contribute to apoptosis via the activation of calpains and/or procaspase-12, which then leads to activation of procaspase-3 (10, 24, 38, 42).”
BackgroundSelf-citation
Cited by
Bagley, W. H., Yang, H., & Shah, K. H. (2007) · Internal and Emergency Medicine · doi:10.1007/s11739-007-0060-8 · Cited by 358
Statin-induced myopathy: a review and update
Abd, T. T., & Jacobson, T. A. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540568 · Cited by 322
Phenotype standardization for statin-induced myotoxicity
Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., Carr, D. F., Bloch, K. M., Fahy, J., Hanson, A., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.121 · Cited by 220
Kwak, H.-B., Thalacker-Mercer, A., Anderson, E. J., Lin, C.-T., Kane, D. A., Lee, N.-S., Cortright, R. N., Bamman, M. M., & Neufer, P. D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.449 · Cited by 114
Bouitbir, J., Charles, A.-L., Rasseneur, L., Dufour, S., Piquard, F., Geny, B., & Zoll, J. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00107.2011 · Cited by 86
Myopathy with statin–fibrate combination therapy: clinical considerations
Jacobson, T. A. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.151 · Cited by 82
Muntean, D. M., Thompson, P. D., Catapano, A. L., Stasiolek, M., Fabis, J., Muntner, P., Serban, M.-C., & Banach, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.001 · Cited by 82
Cheng, A. J., Hwee, D. T., Kim, L. H., Durham, N., Yang, H. T., Hinken, A. C., Kennedy, A. R., Terjung, R. L., Jasper, J. R., Malik, F. I., et al. (2019) · The Journal of Physiology · doi:10.1113/jp278235 · Cited by 41
Dohlmann, T. L., Kuhlman, A. B., Morville, T., Dahl, M., Asping, M., Orlando, P., Silvestri, S., Tiano, L., Helge, J. W., Dela, F., et al. (2022) · Antioxidants · doi:10.3390/antiox11091698 · Cited by 31
Trapani, L., Melli, L., Segatto, M., Trezza, V., Campolongo, P., Jozwiak, A., Swiezewska, E., Pucillo, L. P., Moreno, S., Fanelli, F., et al. (2011) · The FASEB Journal · doi:10.1096/fj.11-184218 · Cited by 25
“To ascertain whether the pharmacological treatment could have caused possible muscle damage, as described previously (2, 8), plasma CKs (22), and muscle cleaved PARP-1 protein levels, markers for muscle fiber necrosis and apoptosis, respectively, were checked (Fig.”
Method
Metadata
- Authors
- Dirks, A. J., & Jones, K. M.
- Venue
- American Journal of Physiology-Cell Physiology
- Publisher
- American Physiological Society
- Published
- 2006-12
- Volume
- 291
- Issue
- 6
- Pages
- C1208-C1212
- ISSN
- 0363-6143 (ISSN-L)
- 1522-1563
- OpenAlex
- W2143607032
- Cited by
- 240
- References
- 1
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.